USD26.94
AstraZeneca / Daiichi Sankyo — Enhertu Redefines First-Line HER2+ Metastatic Breast Cancer Care Enhertu (trastuzumab deruxtecan), an antibody–drug conjugate, became the first ADC approved for first-line treatment of HER2-positive metastatic breast cancer after delivering a marked improvement in progression-free survival versus the long-standing THP standard in the Phase III DESTINY-Breast09 trial Size:20mg https://gmed.nl/wp-content/uploads/ScreenHunter-3045-01-1024x595.png Three Histidine Residues of Amyloid-β Peptide Control the Redox Activity of Copper and Iron | Biochemistry 30%OffExpectOther
USD26.94
USD29.96
USD20.69
Check whether a stated limit affects the quantity or scope you expect. Ask whether a claimed feature depends on an additional selection at checkout.
Check whether your saved contact details are still appropriate. Confirm the currency shown in the final total.
Compare the substitute with your essential requirements. Confirm which optional additions remain compatible when relevant.